{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:47:46Z","timestamp":1784342866982,"version":"3.55.0"},"reference-count":63,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Chantal Biya International Reference Center for Research on HIV and AIDS prevention and management","award":["2020\/2021 Budget Plan"],"award-info":[{"award-number":["2020\/2021 Budget Plan"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Assoc Provid AIDS Care"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In low-and-middle-income-countries (LMIC), viral suppression is defined as plasma viral load (PVL) below 1000 copies\/mL (low-level viremia [LLV]) and threshold for HIV drug resistance (HIVDR) testing. However, there is evidence that drug resistance mutations (DRMs) may emerge at LLV, thus compromising antiretroviral treatment (ART) response. We evaluated sequencing success rates (SSR) at LLV, described HIVDR profiles and adequacy with potential efficacy of tenofovir-lamivudine-dolutegravir (TLD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted among individuals with LLV at the Chantal BIYA International Reference Centre, Yaound\u00e9, Cameroon from January 2020 through August 2021. HIV-1 sequencing was performed on protease\/reverse-transcriptase, and sequences analysed using Stanford HIVdbv9.5. SSR and HIVDR rates were assessed according to viral-load ranges, with P\u2009&lt;\u2009.05 considered statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 131 individuals were enrolled (median [IQR] age = 41 [30\u221249] years; 67.9% female; 54.7% at WHO clinical-stage I\/II; median ART-duration 7 [4\u221211] years; median CD4-count 221 [103\u2212402] cells\/mm\n                      <jats:sup>3<\/jats:sup>\n                      and median PVL 222 [96\u2212436] copies\/mL). Overall, SSR at LLV was 34.4% (45\/131) and increased significantly with decreasing-age ( P\u2009=\u2009.002) and increasing-PVL ( P\u2009=\u2009.017). SSR were doubled at PVL\u2265150 copies\/mL (21.8% at [40\u2212150] vs. 43.3% at [150\u22121000]; OR = 2.8, P\u2009=\u2009.01). Of the 45 sequences obtained, 75.6% were recombinant strains (CRF02_AG, CRF09_cpx, CRF11_cpx) and 24.4% pure-subtypes (A1, D, F2, G). Overall, HIVDR prevalence at LLV was 82.2% (37\/45), with 74.6% and 15.6% resistance to reverse-transcriptase inhibitors (RTIs) and ritonavir-boosted protease inhibitors (PI\/r) respectively. Interestingly, HIVDR rates were similar at PVLs [50\u2212200] versus [200\u22121000] copies\/mL ( P\u2009=\u2009.69). The most frequent DRMs were M184\u2005V (73.3%) and K103N (40.0%) for RTIs and M46I (6.7%) for PIs\/r. Overall 55.6% (25\/45) of individuals were on suboptimal ART (needing ART-optimisation), with 48.9% (22\/45) having suboptimal TLD predictive efficacy. Optimisation need was higher in first-line (81.8%, P\u2009=\u2009.03), but similar across viral clades and PVL-ranges ( P\u2009=\u2009.6).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this LMIC context, sequencing for HIVDR is feasible at LLV even with broad HIV-1 diversity, with significantly higher SSR above 150 copies\/mL and\/or in paediatrics. About 80% of individuals with LLV harbour HIVDR strains, with half of them needing ART optimisations to limit HIVDR emergence and prevent treatment failure. Our findings underscore the clinical benefits of HIVDR during persisting LLV and the need to reconsider the threshold for viral suppression around 200copies\/mL in LMICs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23259582241306484","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T01:56:21Z","timestamp":1734918981000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Plasma Viral Load of 200 Copies\/mL is a Suitable Threshold to Define Viral Suppression and HIV Drug Resistance Testing in Low- and Middle-Income Countries: Evidence From a Facility-Based Study in Cameroon"],"prefix":"10.1177","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6749-1436","authenticated-orcid":false,"given":"Collins Ambe","family":"Chenwi","sequence":"first","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel Audrey","family":"Nayang Mundo","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Protestant University of Central Africa, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Durand","family":"Nka","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"University of Rome Tor Vergata, Rome, Italy"},{"name":"Evangelic University of Cameroon, Bandjoun, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezechiel Ngoufack Jagni","family":"Semengue","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"University of Rome Tor Vergata, Rome, Italy"},{"name":"Evangelic University of Cameroon, Bandjoun, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e2ce Angong","family":"Beloumou","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude Christelle","family":"Ka\u2019e","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy Leroi","family":"Togna Pabo","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Faculty of Health Sciences, University of Buea, Buea, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9","family":"Takou","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aissatou","family":"Abba","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine Claire","family":"Djupsa","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evariste","family":"Molimbou","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"University of Rome Tor Vergata, Rome, Italy"},{"name":"Evangelic University of Cameroon, Bandjoun, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi-karell","family":"Etame","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie Minelle","family":"Kengni Ngueko","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Kob","family":"Same","sequence":"additional","affiliation":[{"name":"National HIV Drug Resistance Group, Ministry of Public Health, Yaound\u00e9, Cameroon"},{"name":"UNAIDS Country Office, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolle Nounouce","family":"Bouba Pamen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"},{"name":"National HIV Drug Resistance Group, Ministry of Public Health, Yaound\u00e9, Cameroon"},{"name":"Department of Disease, Epidemic and Pandemic Control, Ministry of Public Health, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristide Stephane","family":"Abah Abah","sequence":"additional","affiliation":[{"name":"Department of Disease, Epidemic and Pandemic Control, Ministry of Public Health, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge Clotaire","family":"Billong","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"},{"name":"National HIV Drug Resistance Group, Ministry of Public Health, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogers","family":"Ajeh Awoh","sequence":"additional","affiliation":[{"name":"Central Technical Group, National AIDS Control Committee, Ministry of Public Health, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Edie","family":"Halle-Ekane","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Buea, Buea, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cappelli","sequence":"additional","affiliation":[{"name":"National Research Council, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Esther","family":"Njom-Nlend","sequence":"additional","affiliation":[{"name":"Higher Institute of Medical Technology, Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Cecile","family":"ZK Bissek","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"},{"name":"Division of Health Operational Research, Ministry of Public Health, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvis","family":"Temfack","sequence":"additional","affiliation":[{"name":"Africa Centre for Disease Control and Prevention (ACDC), Headquarter, Addis Ababa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Mercedes","family":"Santoro","sequence":"additional","affiliation":[{"name":"University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[{"name":"University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Colizzi","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Protestant University of Central Africa, Yaounde, Cameroon"},{"name":"Evangelic University of Cameroon, Bandjoun, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kaseya","sequence":"additional","affiliation":[{"name":"Africa Centre for Disease Control and Prevention (ACDC), Headquarter, Addis Ababa, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicaise","family":"Ndembi","sequence":"additional","affiliation":[{"name":"Africa Centre for Disease Control and Prevention (ACDC), Headquarter, Addis Ababa, Ethiopia"},{"name":"Institute of Human Virology, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ndjolo","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Federico","family":"Perno","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"University of Rome Tor Vergata, Rome, Italy"},{"name":"Bambino Gesu Pediatric Hospital Rome Italy, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fokam","sequence":"additional","affiliation":[{"name":"Chantal BIYA International Reference Centre for Research on HIV\/AIDS Prevention and Management, Yaound\u00e9, Cameroon"},{"name":"Faculty of Health Sciences, University of Buea, Buea, Cameroon"},{"name":"Faculty of Medicine and Biomedical Sciences, University of Yaound\u00e9 I, Yaound\u00e9, Cameroon"},{"name":"National HIV Drug Resistance Group, Ministry of Public Health, Yaound\u00e9, Cameroon"},{"name":"Central Technical Group, National AIDS Control Committee, Ministry of Public Health, Yaounde, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"key":"bibr1-23259582241306484","unstructured":"2023-global-aids-monitoring_en.pdf. Accessed Jul 27, 2023. https:\/\/indicatorregistry.unaids.org\/sites\/default\/files\/2023-global-aids-monitoring_en.pdf"},{"key":"bibr2-23259582241306484","unstructured":"The path that ends AIDS: UNAIDS Global AIDS Update 2023. UPDATE. 2023."},{"key":"bibr3-23259582241306484","unstructured":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents | AIDS education and training centers national coordinating resource center (AETC NCRC). 2022. https:\/\/aidsetc.org\/resource\/guidelines-use-antiretroviral-agents-hiv-1-infected-adults-and-adolescents"},{"key":"bibr4-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002306"},{"key":"bibr5-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30418-0"},{"key":"bibr6-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5148"},{"key":"bibr7-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30132-2"},{"key":"bibr8-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00877-2"},{"key":"bibr9-23259582241306484","unstructured":"guidelines-11.1_final_09-10.pdf. Accessed July 27, 2023. https:\/\/www.eacsociety.org\/media\/guidelines-11.1_final_09-10.pdf"},{"key":"bibr10-23259582241306484","unstructured":"Virologic Failure | NIH [Internet]. 2023. Accessed July 22, 2023. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/virologic-failure"},{"key":"bibr11-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000544"},{"key":"bibr12-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13250"},{"key":"bibr13-23259582241306484","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2815"},{"key":"bibr14-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit529"},{"key":"bibr15-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir353"},{"key":"bibr16-23259582241306484","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3023"},{"key":"bibr17-23259582241306484","unstructured":"WHO announces the update of the Consolidated Guidelines on HIV Testing Services (update 2022-23). Accessed July 27, 2023. https:\/\/www.who.int\/news\/item\/20-10-2022-who-announces-the-update-of-the-consolidated-guidelines-on-hiv-testing-services-update-2022-23"},{"key":"bibr18-23259582241306484","unstructured":"New WHO guidance on HIV viral suppression and scientific updates released at IAS 2023 [Internet]. Accessed July 27, 2023. https:\/\/www.who.int\/news\/item\/23-07-2023-new-who-guidance-on-hiv-viral-suppression-and-scientific-updates-released-at-ias-2023"},{"key":"bibr19-23259582241306484","unstructured":"3471CAMPHIA_Cameroon-SS_A4_v13_requests_7.25.18.pdf. Accessed July 27, 2023. https:\/\/phia.icap.columbia.edu\/wp-content\/uploads\/2018\/07\/3471CAMPHIA_Cameroon-SS_A4_v13_requests_7.25.18.pdf"},{"key":"bibr20-23259582241306484","unstructured":"Comite National de Lutte le SIDA (CNLS). Rapport Annuel des activitees de lutte contre le VIH et SIDA 2021. 2022. https:\/\/cnls.cm\/index.php\/rapports-dactivites\/"},{"key":"bibr21-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2021.2004743"},{"key":"bibr22-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx042"},{"key":"bibr23-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1177\/2325957416680028"},{"key":"bibr24-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00462-4"},{"key":"bibr25-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30681-3"},{"key":"bibr26-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03771-14"},{"key":"bibr27-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4979252"},{"key":"bibr28-23259582241306484","unstructured":"Santoro MM, Perno CF. Clinical relevance of genotypic resistance testing today.\n                      New Microbiol\n                      . 2016 Apr;39(2):91\u201392."},{"key":"bibr29-23259582241306484","unstructured":"MINSANTE. DIRECTIVES NATIONALES SUR LA PRISE EN CHARGE DU VIH. 2021."},{"key":"bibr30-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-011-0982-3"},{"key":"bibr31-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab004"},{"key":"bibr32-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu019"},{"key":"bibr33-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab220"},{"key":"bibr34-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2010.04.008"},{"key":"bibr35-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2015.09.006"},{"key":"bibr36-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23846"},{"key":"bibr37-23259582241306484","doi-asserted-by":"publisher","DOI":"10.3390\/v15071458"},{"key":"bibr38-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01217-12"},{"key":"bibr39-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0395-4"},{"key":"bibr40-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2010.010292"},{"key":"bibr41-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-2092-z"},{"key":"bibr42-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab293"},{"key":"bibr43-23259582241306484","unstructured":"HIV drug resistance report 2019. Accessed November 14, 2022. https:\/\/www.who.int\/publications-detail-redirect\/WHO-CDS-HIV-19.21"},{"key":"bibr44-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31822db54c"},{"issue":"2","key":"bibr45-23259582241306484","first-page":"53","volume":"5","author":"Dambaya B","year":"2020","journal-title":"Explor Res Hypo Med"},{"key":"bibr46-23259582241306484","unstructured":"Monitoring HIV disease progression in children. Accessed August 22, 2024. http:\/\/www.hivinchildren.org\/topic.aspx?id=63"},{"key":"bibr47-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-019-0165-8"},{"key":"bibr48-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad626"},{"key":"bibr49-23259582241306484","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.944990"},{"key":"bibr50-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa510"},{"key":"bibr51-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2016.08.031"},{"key":"bibr52-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1007\/s40471-021-00268-3"},{"key":"bibr53-23259582241306484","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2949"},{"key":"bibr54-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(24)00063-8"},{"key":"bibr55-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282652"},{"key":"bibr56-23259582241306484","unstructured":"HIV diagnostic tests in low- and middle-income countries: forecasts of global demand for 2021-2025. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240042261"},{"key":"bibr57-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1086\/430709"},{"key":"bibr58-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00777.x"},{"key":"bibr59-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02154-08"},{"key":"bibr60-23259582241306484","unstructured":"WHO publishes new Consolidated HIV guidelines for prevention, treatment, service delivery & monitoring. 2021. https:\/\/www.who.int\/news\/item\/16-07-2021-who-publishes-new-consolidated-hiv-guidelines-for-prevention-treatment-service-delivery-monitoring"},{"key":"bibr61-23259582241306484","first-page":"123","author":"Taramasso L","year":"2020","journal-title":"J Clin Virol."},{"key":"bibr62-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa373"},{"key":"bibr63-23259582241306484","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00543-23"}],"container-title":["Journal of the International Association of Providers of AIDS Care (JIAPAC)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582241306484","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23259582241306484","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23259582241306484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:50:34Z","timestamp":1777503034000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23259582241306484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":63,"alternative-id":["10.1177\/23259582241306484"],"URL":"https:\/\/doi.org\/10.1177\/23259582241306484","relation":{},"ISSN":["2325-9582","2325-9582"],"issn-type":[{"value":"2325-9582","type":"print"},{"value":"2325-9582","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"23259582241306484"}}